Paul Anderson, NMD - Case Studies (2017 Conference) (LDN, low dose naltrexone)

The first case is an oncology patient, a 47 year old female with colorectal cancer.  This lady presented herself while halfway through standard cancer treatment.  Dr Anderson added many adjunct therapies as well as Low Dose Naltrexone and the patients tumour markers reduced for the first time.

  • Chronic plaque psoriasis, which is the most common type, this usually presents on the knees, elbows, trunk, scalp, behind the ears and between the buttocks although other areas can be involved too.
  • Guttate psoriasis which consists of small plaques of psoriasis scatters over the trunk and limbs – this can be caused by streptococcus bacteria which can cause sore throats.
  • Palmoplantar psoriasis more commonly affects the palms and soles of the feet.
  • Pustular psoriasis is rare, but like guttate psoriasis, it affects the trunk and limbs but comes with y

Pharmacist Kim Hansen, LDN Radio Show 30 Oct 2019 (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.

Linda Elsegood: Today, my guest is pharmacist Kim Hansen. She's from the Town and Country Compounding Pharmacy in New Jersey. Thank you for joining us today, Kim. 

Dickson Chemist developed a new formulation of LDN which will hopefully improve the outcomes for patients. This new formulation is a more concentrated liquid in the form of drops which are administered under the tongue and absorbed directly from the mucosal lining of the mouth. This sublingual route produces a more rapid absorption bypassing the liver and digestive tract. There are several potential advantages to this, the drug may be more effective and will not be affected by the presence of food stuffs or the hostile environment of the gut.

Subscribe to Immune